Amit Etkin

1 month ago | psychiatrictimes.com | Amit Etkin |Heidi Anne Duerr

Alto Neuroscience is rapidly expanding its clinical pipeline with four ongoing phase 2 trials, all incorporating precision psychiatry approaches to target unmet needs in psychiatric treatment, Amit Etkin, MD, PhD, founder and CEO of Alto Neuroscience, told Psychiatric Times in a recent interview.

1 month ago | psychiatrictimes.com | Amit Etkin |Heidi Anne Duerr

At the 2025 Society of Biological Psychiatry meeting in Toronto, Canada, Alto Neuroscience shared new data and findings on machine-learning-derived biomarker and the biological mechanism of action behind its investigational antidepressant, ALTO-300.1,2 In an exclusive interview with Psychiatric Times, Amit Etkin, MD, PhD, founder and CEO of Alto Neuroscience, described the significance of this research for advancing precision psychiatry.

1 month ago | psychiatrictimes.com | Amit Etkin |Heidi Anne Duerr

Author(s):,At the recent Society of Biological Psychiatry meeting in Toronto, Canada, Alto Neuroscience presented 6 posters highlighting its ongoing efforts in biomarker-driven drug development.1,2 In an exclusive interview with Psychiatric Times, Amit Etkin, MD, PhD, founder and CEO of Alto, discussed the 2 key research themes: predicting placebo response and advancing precision psychiatry via biomarkers and what the research means for the future of psychiatry.

Aug 20, 2024 | nature.com | Amit Etkin

AbstractNeuroimaging, across positron emission tomography (PET), electroencephalography (EEG), and magnetic resonance imaging (MRI), has been a mainstay of clinical neuroscience research for decades, yet has penetrated little into psychiatric drug development beyond often underpowered phase 1 studies, or into clinical care. Simultaneously, there is a pressing need to improve the probability of success in drug development, increase mechanistic diversity, and enhance clinical efficacy.

Mar 8, 2024 | statnews.com | Amit Etkin

Your go-to source for the latest news and insights in the world of life sciences, medicine, biotech, and pharma Join the conversation at exclusive live and virtual events hosted by STAT Stay ahead with subscriber-only newsletters delivered to your inbox daily Make data-driven decisions with our premium data tools Your go-to source for the latest news and insights in the world of life sciences, medicine, biotech, and pharma Join the conversation at exclusive live and virtual events hosted by...